We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+19.81%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.35B
AUM Growth
+$99.6M
Cap. Flow
+$46.9M
Cap. Flow %
3.47%
Top 10 Hldgs %
51.22%
Holding
199
New
40
Increased
30
Reduced
31
Closed
45

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$43.2M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$19.8M
3
BAX icon
Baxter International
BAX
+$15.5M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$13.3M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$11.5M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$22.7M
2
RLYP
RELYPSA INC COM
RLYP
+$18.3M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$17.6M
4
CEMP
Cempra, Inc.
CEMP
+$16.2M
5
SHPG
Shire pic
SHPG
+$8.41M

Sector Composition

Rank Sector Weight
1 Healthcare 88.87%
2 Miscellaneous 10.46%
3 Consumer Staples 0.55%
4 Consumer Discretionary 0.08%
5 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EVH icon
76
Evolent Health
EVH
$423M
$1.79M 0.13%
147,600
+10,311
+8% +$152K
ABEOW
77
DELISTED
Abeona Therapeutics Inc Warrant
ABEOW
$1.66M 0.12%
1,259,636
– –
XENE icon
78
Xenon Pharmaceuticals
XENE
$5.45B
$1.66M 0.12%
205,800
– –
INDP icon
79
Indaptus Therapeutics
INDP
$485M
$1.47M 0.11%
123
-33
-21% -$424K
CSBR icon
80
Champions Oncology
CSBR
$66.4M
$1.33M 0.1%
372,597
– –
NVTA
81
DELISTED
Invitae Corporation
NVTA
$1.18M 0.09%
143,366
-108,300
-43% -$852K
SAGE
82
DELISTED
Sage Therapeutics
SAGE
$1.17M 0.09%
20,000
– –
GNVC
83
DELISTED
GenVec, Inc.
GNVC
$1.13M 0.08%
61,584
– –
SCYX icon
84
SCYNEXIS
SCYX
$43.7M
$1.09M 0.08%
2,188
– –
ALPN
85
DELISTED
Alpine Immune Sciences Inc
ALPN
$968K 0.07%
31,250
– –
CGNT
86
DELISTED
Cogentix Medical, Inc.
CGNT
$869K 0.06%
673,257
– –
STLA icon
87
Stellantis
STLA
$14.8B
$867K 0.06%
95,090
– –
VCEL icon
88
Vericel Corp
VCEL
$2.03B
$789K 0.06%
305,662
-45,500
-13% -$102K
NGNE icon
89
Neurogene
NGNE
$674M
$744K 0.06%
2,980
– –
VNDA icon
90
Vanda Pharmaceuticals
VNDA
$302M
$669K 0.05%
+71,849
New +$717K
XIV
91
DELISTED
VelocityShares Daily Inverse VIX Short Term ETN
XIV
$645K 0.05%
25,000
-21,500
-46% -$620K
IMMU
92
DELISTED
Immunomedics Inc
IMMU
$614K 0.05%
+200,000
New +$558K
GRCE
93
Grace Therapeutics
GRCE
$46.9M
$594K 0.04%
4,928
– –
DRNA
94
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$594K 0.04%
50,000
– –
ANIP icon
95
ANI Pharmaceuticals
ANIP
$1.66B
$578K 0.04%
12,800
-6,456
-34% -$278K
EOCN
96
Eocene Ltd. Ordinary Shares
EOCN
$3.88M
$571K 0.04%
52
– –
NVO
97
Novo Nordisk
NVO
$188B
$554K 0.04%
19,080
+8,400
+79% +$232K
STML
98
DELISTED
Stemline Therapeutics, Inc.
STML
$496K 0.04%
78,603
– –
AVGR
99
DELISTED
Avinger, Inc. Common Stock
AVGR
– –
-1
Closed -$2.09M
MACK
100
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$395K 0.03%
+6,355
New +$447K
2 3
4
5 6

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q4 2015 Portfolio in Review

As of Q4 2015, Perceptive Advisors held 199 positions worth $1.35B, up 8% from $1.25B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Perceptive Advisors deployed $46.9M of net new capital in Q4 2015, opening 40 new positions and adding to 30 existing holdings. Its largest new stake was Allergan plc: 145,000 shares worth $45.3M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 81% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was Neurocrine Biosciences, an estimated $22.7M trimmed.

  • Perceptive Advisors's largest Q4 2015 buy was Allergan plc: 145,000 shares worth $45.3M.
  • Perceptive Advisors added most to Teva Pharmaceuticals in Q4 2015, an estimated $19.8M increase.
  • Perceptive Advisors's biggest Q4 2015 reduction was Neurocrine Biosciences, cutting an estimated $22.7M.
  • Perceptive Advisors fully exited RELYPSA INC COM in Q4 2015, selling an estimated $18.3M.
  • Perceptive Advisors's ten largest holdings make up 51% of its $1.35B portfolio in Q4 2015.
  • Perceptive Advisors opened 40 new positions and closed 45 in Q4 2015.
  • Perceptive Advisors's portfolio value rose 8% quarter-over-quarter to $1.35B.

Based on Perceptive Advisors's 13F filing for Q4 2015, filed 16 Feb 2016.